Friday October 20th 2017

[Articles] Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Teriflunomide 14 mg was associated with a lower relapse rate and less disability accumulation compared with placebo, with a similar safety and tolerability profile to that reported in previous studies. These results confirm the dose effect reported in previous trials and support the use of teriflunomide 14 mg in patients with relapsing multiple sclerosis. (Source: Lancet Neurology)

Original article:  

[Articles] Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Leave a Comment

More from category

OHSU’s Robertson on coming to grips with his diagnosis
OHSU’s Robertson on coming to grips with his diagnosis

After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other [Read More]

Concussion in teens increase risk of multiple sclerosis
Concussion in teens increase risk of multiple sclerosis

Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They [Read More]

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk

A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple [Read More]

Multiple sclerosis: Oligodendrocytes from stemmcells
Multiple sclerosis: Oligodendrocytes from stemmcells

(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the [Read More]

Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr
Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr

/About-the-Society/News/Global-Experts-Publish-Recommendations-for-Overcom [Read More]